Study: Cardiodiabesity prevention key to improving health outcomes and lowering costs
The Evernorth Research Institute analyzed aggregated and anonymized data of almost 5 million insured individuals to understand the prevalence of "cardiodiabesity" — a condition which encompasses cardi...
September 07, 23Read More
Designing plans to manage comorbid conditions
Health plans that address and manage complex chronic conditions such as cardiovascular disease, obesity, and diabetes have a competitive advantage.
Daniel Chambers, PharmD, August 25, 23Read More
Tipping the scales to effectively treat obesity
The promise and challenges of semaglutide, a new therapy for weight loss
Christine Gilroy, MD, MSPH, August 02, 23Read More
Addressing obesity in the workplace
As more people turn to diabetes medication to manage their weight, obesity has become a pressing concern for employers.
Christine Gilroy, MD, MSPH, July 26, 23Read More
Clinically Speaking: GLP-1s Medications 101
GLP-1 medications are FDA-approved specifically for weight loss for more than half the adult population in the United States. Plan sponsors can take action to manage weight and other cardiodiabesity-r...
Christine Gilroy, MD, MSPH, July 25, 23Read More
Clinically Speaking: Cardiodiabesity 101
More than half of U.S. adults suffer from cardiovascular disease, diabetes or obesity and a growing number experience all three. Plan sponsors can take action to address this increasingly complex chal...
Christine Gilroy, MD, MSPH, July 13, 23Read More